posted on 2020-02-24, 21:44authored byYuguang Zhao, Jingshan Ren, James Hillier, Weixian Lu, E. Yvonne Jones
Misregulation
of Wnt signaling is common in human cancer. The development
of small molecule inhibitors against the Wnt receptor, frizzled (FZD),
may have potential in cancer therapy. During small molecule screens,
we observed binding of carbamazepine to the cysteine-rich domain (CRD)
of the Wnt receptor FZD8 using surface plasmon resonance (SPR). Cellular
functional assays demonstrated that carbamazepine can suppress FZD8-mediated
Wnt/β-catenin signaling. We determined the crystal structure
of the complex at 1.7 Å resolution, which reveals that carbamazepine
binds at a novel pocket on the FZD8 CRD. The unique residue Tyr52
discriminates FZD8 from the closely related FZD5 and other FZDs for
carbamazepine binding. The first small molecule-bound FZD structure
provides a basis for anti-FZD drug development. Furthermore, the observed
carbamazepine-mediated Wnt signaling inhibition may help to explain
the phenomenon of bone loss and increased adipogenesis in some patients
during long-term carbamazepine treatment.